Chemistry:CYB004

From HandWiki

CYB004, or CYB-004, also known as deuterated dimethyltryptamine (dDMT), is a serotonergic psychedelic related to dimethyltryptamine (DMT) which is under development for the treatment of generalized anxiety disorder.[1][2][3][4][5] It is administered by inhalation or intravenous injection.[1][3]

It is a tryptamine derivative and is a deuterated analogue and form of DMT.[1][2][4] The pharmacodynamic profile of CYB004, including its interactions with serotonin receptors and its effects in animals, is similar to that of DMT.[4] As with DMT, CYB004 is a potent agonist of the serotonin 5-HT2A receptor and produces psychedelic-like effects in animals.[1][6][4] However, CYB004, due to its deuteration, is more resistant to metabolism than DMT and shows a longer elimination half-life (by 2.5- to 2.9-fold) and slower clearance (by 38 to 55%) in animals.[4] The brain to plasma ratio of CYB004 was also increased (by 30%) relative to DMT, indicating slightly greater central permeability as well.[4]

As of August 2024, CYB004 is in phase 2 clinical trials for generalized anxiety disorder.[1][2] It was also under development for the treatment of substance-related disorders and of other psychiatric disorders, but development for these indications was discontinued.[1] The drug is under development by Cybin.[1][2] The exact chemical structure of CYB004 (i.e., which hydrogen atoms are deuterated) does not yet seem to have been disclosed.[1] However, Cybin patented deuterated tryptamines, including deuterated forms of DMT like DMT-d10, in 2023.[7] Other related drugs include the deuterated tryptamine CYB003 and the deuterated phenethylamines CYB005 and CYB210010.[6][3]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 "CYB 004". 14 August 2024. https://adisinsight.springer.com/drugs/800062410. 
  2. ↑ 2.0 2.1 2.2 2.3 "Delving into the Latest Updates on Deuterated dtryptamine with Synapse". 27 October 2024. https://synapse.patsnap.com/drug/8577e733c46648599fdd96ed1661ea3b. 
  3. ↑ 3.0 3.1 3.2 "Next-generation psychedelics: should new agents skip the trip?". Nature Biotechnology 42 (6): 827–830. June 2024. doi:10.1038/s41587-024-02285-1. PMID 38831049. 
  4. ↑ 4.0 4.1 4.2 4.3 4.4 4.5 "ACNP 62nd Annual Meeting: Poster Abstracts P1 - P250: P80. Preclinical Characterization of CYB004: A Novel, Deuterated N,N-Dimethyltryptamine (DMT) Analog for the Potential Treatment of Generalized Anxiety Disorder (GAD)". Neuropsychopharmacology (Springer Science and Business Media LLC) 48 (Suppl 1): 63–210 (109–110). December 2023. doi:10.1038/s41386-023-01755-5. PMID 38040809. 
  5. ↑ "ACNP 62nd Annual Meeting: Poster Abstracts P251 – P500: P425. Early Clinical Development of a Deuterated N,N-Dimethyltryptamine (DMT) Analog for the Treatment of Mental Health Conditions". Neuropsychopharmacology 48 (Suppl 1): 211–354 (310–311). December 2023. doi:10.1038/s41386-023-01756-4. PMID 38040810. 
  6. ↑ 6.0 6.1 "Key Characteristics and Development of Psychoceuticals: A Review". International Journal of Molecular Sciences 23 (24). December 2022. doi:10.3390/ijms232415777. PMID 36555419. 
  7. ↑ Nivorozhkin A, Palfreyman M, "Deuterated tryptamine derivatives and methods of use", US patent 2023/0357147, published 8 October 2024



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:CYB004&oldid=4178158"